News Release

GNI Group Ltd. is pleased to announce the acquisition by its consolidated subsidiary Beijing Continent Pharmaceutical Co., Ltd. of additional land for expansion of its EtuaryR API manufacturing facilities. The company recently acquired approximately 50 mu (approximately 33,330 ㎡) located in the Cangzhou Bohai New Area Biomedical Industrial Park, Hebei Province and will begin construction of a new API factory in early 2017. The new manufacturing base will enable BC to increase API product capacity by 10 fold to meet any potential increase in demand for its flagship drug EtuaryR in the future, in addition to meeting higher environmental protection standards.